Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
- PMID: 39725693
- PMCID: PMC11671601
- DOI: 10.1038/s41746-024-01370-8
Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Abstract
In silico trials for drug safety assessment require many high-fidelity 3D cardiac simulations to predict drug-induced QT interval prolongation, which is often computationally prohibitive. To streamline this process, we developed sex-specific emulators for a fast prediction of QT interval, trained on a dataset of 900 simulations. Our results show significant differences between 3D and 0D single-cell models as risk levels increase, underscoring the ability of 3D modeling to capture more complex cardiac responses. The emulators demonstrated an average error of 4% compared to simulations, allowing for efficient global sensitivity analysis and fast replication of in silico clinical trials. This approach enables rapid, multi-dose drug testing on standard hardware, addressing critical industry challenges around trial design, assay variability, and cost-effective safety evaluations. By integrating these emulators into drug development, we can improve preclinical reliability and advance the practical application of digital twins in biomedicine.
© 2024. The Author(s).
Conflict of interest statement
Competing interests: P.D., A.Z., L.B., C.B., B.D. and J.A. declare no competing interests. M.V. is CTO and co-founder of ELEM Biotech and C.M. is CEO and co-founder of ELEM Biotech.
Figures
References
-
- National Health Service. Arrhythmia (2021). https://www.nhs.uk/conditions/arrhythmia/. Accessed July 31, 2024.
-
- Cubeddu, L. QT Prolongation and Fatal Arrhythmias: A Review of Clinical Implications and Effects of Drugs. American journal of therapeutics10, 452–7 (2003). - PubMed
-
- Sager, P. T., Gintant, G., Turner, J. R., Pettit, S. & Stockbridge, N. Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the cardiac safety research consortium. American Heart Journal167, 292–300 (2014). - PubMed
-
- Gintant, G., Sager, P. T. & Stockbridge, N. Evolution of strategies to improve preclinical cardiac safety testing. Nature Reviews Drug Discovery15, 457–471 (2016). - PubMed
-
- Kaye, G. & Lemery, R.Fast Facts: Cardiac Arrhythmias (S. Karger AG, 2018).
Grants and funding
LinkOut - more resources
Full Text Sources
